About
Colinz Laboratories Limited manufactures and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynaecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin, etc.; antiritrovirals comprising lopinavir, indinavir, ritonavir, darunavir, zidovudine, lamivudin, and various combination therapy products; and products for other therapeutic areas, such as antibiotics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anthelmintics, anti-emetics, anti-inflammatory (NSAIDS), sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, digestive enzymes, topical steroids, ear/eye drops, hormones, sunscreens, vitamins, etc., as well as drugs used in protozoal infestations and neuropathy. In addition, the company offers ayurvedic products comprising anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, memory boosters, anti-piles, antacids, liver tonics, ulcer healing agents, digestive agents, uterine tonics, anti-diabetics, and general tonics, as well as drugs to treat oligospermia and erectile dysfunction. Further, it provides nutraceuticals, including spirulina tabs/caps, spirulina with vitamins and minerals, omega 3 fatty acids caps in softgel, codliver oil with vitamin caps in soft gel, amino acids tabs/caps, l-arginine with proantocyanidin granules, and hair growth formulations, etc., as well as collagen, glucosamine, and chondroitin tabs. Colinz Laboratories Limited was incorporated in 1986 and is based in Mumbai, India.
Key Metrics
as of Sep 2026Quarterly Results
Rs. Crores Β· hover row for definition| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.24 | 1.75 | 1.43 | 1.39 | 1.57 | 1.45 | 1.47 | 1.86 | 1.75 | 1.63 | 1.71 | 1.79 | 1.90 |
| Expenses | 1.18 | 1.66 | 1.33 | 1.31 | 1.44 | 1.35 | 1.40 | 1.69 | 1.59 | 1.51 | 1.57 | 1.67 | 1.74 |
| Operating Profit | 0.06 | 0.09 | 0.10 | 0.08 | 0.13 | 0.10 | 0.07 | 0.17 | 0.16 | 0.12 | 0.14 | 0.12 | 0.16 |
| OPM % | 4.84 | 5.14 | 6.99 | 5.76 | 8.28 | 6.90 | 4.76 | 9.14 | 9.14 | 7.36 | 8.19 | 6.70 | 8.42 |
| Other Income | 2.89 | 0.17 | 0.08 | 0.16 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.11 | 0.05 | 0.08 | 0.04 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Interest | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Profit before tax | 2.90 | 0.21 | 0.13 | 0.19 | 0.16 | 0.13 | 0.11 | 0.21 | 0.19 | 0.19 | 0.15 | 0.16 | 0.16 |
| Tax % | 17.24 | 19.05 | 30.77 | 26.32 | 25.00 | -23.08 | 45.45 | 23.81 | 26.32 | 31.58 | 26.67 | 25.00 | 18.75 |
| Net Profit | 2.40 | 0.17 | 0.08 | 0.14 | 0.12 | 0.15 | 0.05 | 0.16 | 0.14 | 0.14 | 0.11 | 0.12 | 0.12 |
| EPS in Rs | 9.53 | 0.67 | 0.32 | 0.56 | 0.48 | 0.60 | 0.20 | 0.64 | 0.56 | 0.56 | 0.44 | 0.48 | 0.48 |
Profit & Loss
Annual Β· Rs. Crores| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.14 | 6.53 | 7.03 | 7.15 | 6.97 | 6.16 | 7.53 | 7.59 | 7.83 | 8.05 | 8.10 | 7.88 |
| Expenses | 5.72 | 6.04 | 6.49 | 6.52 | 6.38 | 5.82 | 7.22 | 7.24 | 7.48 | 7.64 | 7.65 | 7.42 |
| Operating Profit | 0.42 | 0.49 | 0.54 | 0.63 | 0.59 | 0.34 | 0.31 | 0.35 | 0.35 | 0.41 | 0.45 | 0.46 |
| OPM % | 6.84 | 7.50 | 7.68 | 8.81 | 8.46 | 5.52 | 4.12 | 4.61 | 4.47 | 5.09 | 5.56 | 5.84 |
| Other Income | 0.48 | 0.30 | 0.28 | 0.15 | 0.17 | 0.19 | 0.13 | 0.12 | 0.10 | 0.09 | 0.10 | 0.10 |
| Interest | 0.05 | 0.04 | 0.04 | 0.05 | 0.08 | 0.09 | 0.07 | 0.10 | 0.08 | 0.12 | 0.12 | 0.12 |
| Depreciation | 0.16 | 0.13 | 0.13 | 0.13 | 0.20 | 0.19 | 0.19 | 0.22 | 0.22 | 0.27 | 0.28 | 0.30 |
| Profit before tax | 0.69 | 0.62 | 0.65 | 0.60 | 0.48 | 0.25 | 0.18 | 0.15 | 0.15 | 0.11 | 0.15 | 0.14 |
| Tax % | 24.64 | 20.97 | 26.15 | 23.33 | 29.17 | 16.00 | 27.78 | 26.67 | -53.33 | -27.27 | 40.00 | 35.71 |
| Net Profit | 0.51 | 0.50 | 0.49 | 0.46 | 0.34 | 0.21 | 0.13 | 0.12 | 0.23 | 0.14 | 0.09 | 0.10 |
| EPS in Rs | 2.02 | 1.98 | 1.95 | 1.83 | 0.74 | 0.46 | 0.28 | 0.26 | 0.50 | 0.31 | 0.20 | 0.22 |
| Dividend Payout % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance Sheet
Annual Β· Rs. Crores β latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.52 | 2.52 | 2.52 | 2.52 | 3.55 | 3.55 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 | 3.54 |
| Reserves | 7.52 | 6.96 | 6.43 | 5.62 | 4.14 | 3.75 | 3.29 | 3.30 | 3.21 | 2.98 | 2.71 | 2.62 |
| Borrowings | 0.39 | 0.64 | 0.57 | 0.27 | 0.48 | 0.99 | 0.38 | 0.68 | 0.42 | 0.76 | 1.80 | 2.53 |
| Other Liabilities | 2.35 | 1.70 | 1.84 | 1.82 | 1.76 | 1.81 | 1.60 | 1.65 | 2.42 | 2.40 | 1.70 | 1.97 |
| Total Liabilities | 12.78 | 11.82 | 11.36 | 10.23 | 9.93 | 10.10 | 8.81 | 9.17 | 9.59 | 9.68 | 9.75 | 10.66 |
| Fixed Assets | 1.54 | 1.70 | 1.58 | 1.71 | 1.86 | 2.03 | 2.06 | 2.21 | 2.41 | 2.63 | 2.88 | 3.16 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.11 | 1.04 | 1.02 | 0.66 | 0.67 | 0.61 | 0.36 | 0.50 | 0.53 | 0.41 | 0.29 | 0.29 |
| Other Assets | 10.13 | 9.08 | 8.76 | 7.86 | 7.40 | 7.46 | 6.39 | 6.46 | 6.65 | 6.64 | 6.58 | 7.21 |
| Total Assets | 12.78 | 11.82 | 11.36 | 10.23 | 9.93 | 10.10 | 8.81 | 9.17 | 9.59 | 9.68 | 9.75 | 10.66 |
Cash Flows
Annual Β· Rs. Crores β latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 2.54 | -1.45 | 1.03 | 0.40 | 0.47 | 2.16 | 0.58 | 0.12 | 0.34 | 0.06 | 0.58 | 0.09 |
| Cash from Investing Activity | 0.01 | -0.23 | 0.01 | 0.01 | -0.03 | -0.16 | -0.04 | -0.01 | -0.11 | -0.01 | 0.00 | 0.03 |
| Cash from Financing Activity | 0.43 | 0.24 | 0.23 | 0.11 | 0.09 | 0.08 | 0.06 | 0.02 | 0.01 | -0.03 | -0.73 | 0.45 |
| Net Cash Flow | 2.98 | -1.45 | 1.27 | 0.52 | 0.52 | 2.07 | 0.60 | 0.12 | 0.24 | 0.02 | -0.16 | 0.57 |
| Free Cash Flow | 2.54 | -1.71 | 1.03 | 0.40 | 0.43 | 2.00 | 0.54 | 0.12 | 0.34 | 0.04 | 0.58 | 0.09 |
| CFO/OP % | 650.00 | -253.00 | 224.00 | 89.00 | 105.00 | 659.00 | 210.00 | 43.00 | 106.00 | 22.00 | 136.00 | 26.00 |
Ratios
Annual Β· Days / % β latest first| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 49.93 | 36.89 | 44.65 | 57.69 | 63.36 | 77.03 | 72.22 | 80.79 | 78.31 | 66.65 | 60.83 | 62.53 |
| Inventory Days | 148.55 | 136.22 | 134.31 | 149.17 | 147.59 | 208.33 | 225.13 | 246.80 | 266.31 | 267.25 | 232.18 | 288.96 |
| Days Payable | 80.64 | 94.31 | 94.81 | 103.15 | 76.17 | 90.00 | 49.29 | 44.16 | 91.93 | 55.68 | 60.66 | 116.24 |
| Cash Conversion Cycle | 117.84 | 78.81 | 84.15 | 103.71 | 134.78 | 195.36 | 248.06 | 283.42 | 252.70 | 278.23 | 232.35 | 235.25 |
| Working Capital Days | -60.64 | 73.22 | -22.84 | 11.23 | 9.95 | 0.00 | 79.01 | 89.45 | 72.72 | 71.19 | 100.04 | 110.24 |
| ROCE % | 7.20 | 6.62 | 7.70 | 8.08 | 6.80 | 4.39 | 3.39 | 3.40 | 3.18 | 3.00 | 3.23 | 3.20 |
Corporate Actions
No corporate actions recorded.